// App-Quantinova.ai

54 : Effect of sarilumab on glycosylated hemoglobin in patients with rheumatoid arthritis and diabetes

Researchers

Presenter

  • Gerd R Burmester

Principal Investigators

  • Owen Hagino

  • Hubert van Hoogstraten

  • Erin Mangan

  • Karthinathan Thangavelu

  • Roy Fleischmann

  • Elaine Wilson

  • Thomas Mandrup-Poulsen

Medical Centers

  • Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany

  • Clinical Science, Sanofi Genzyme, Bridgewater, NJ

  • Medical Affairs, Sanofi, Bridgewater, NJ, USA

  • Medical Analytics, Medical Affairs, Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA

  • Biostatistics, Sanofi Genzyme, Bridgewater, NJ

  • Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX

  • Rheumatology, Sanofi Genzyme, Oxford, UNITED KINGDOM

  • Inflammation, Metabolism, and Oxidation, University of Copenhagen, Copenhagen, DENMARK

Locations

  • Germany

  • United States

  • United Kingdom

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Rheumatoid arthritis

  • Diabetes

Biomarkers

  • Hemoglobin A1c

Drug/Treatment

  • Adalimumab

  • Sarilumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT01709578

  • NCT02332590

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved